Original article—alimentary tractLifetime and Treatment-Phase Costs Associated With Colorectal Cancer: Evidence from SEER-Medicare Data
Section snippets
Data Sources
This study used 3 data sources: (1) the linked Surveillance Epidemiology and End Results (SEER)–Medicare database (a collaborative effort of the National Cancer Institute, the SEER registries, and the Centers for Medicare and Medicaid Services); (2) the SEER*Stat database, containing clinical and survival data from the SEER registries; and (3) survival data for the general population from US life-tables.
SEER is a US cancer surveillance system consisting of population-based tumor registries
Patient Characteristics
We identified 56,838 CRC patients (41,256 colon cancer [CC], 15,582 rectal cancer [RC]) who met our selection criteria. Demographic and clinical characteristics for CC patients, RC patients, the combined CRC cohort, and the comparison cohort are presented in Table 1. The mean ± SD age was 77.7 ± 7.1 years; about 55% of patients in both cohorts were women and 86% were white.
Lifetime Cost Estimates
Total lifetime cancer-related costs were $28,500, with an inverted U-shaped pattern by stage and a U-shaped pattern by age (
Discussion
This study evaluated lifetime and phase-specific excess costs among elderly patients with CRC in the United States. We found that lifetime CRC-related costs are substantial and vary by cancer subsite, stage at diagnosis, age at diagnosis, and treatment phase. Excess lifetime costs show an inverted U-shaped pattern by stage at diagnosis, and a U-shaped pattern by age at diagnosis for both CC and RC. Costs for RC patients are lower than costs for CC patients in stage 0, higher in stages I to III,
References (23)
- et al.
Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis
Gastroenterology
(2004) - et al.
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
J Clin Epidemiol
(1992) - et al.
Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer
Am J Gastroenterol
(2002) - et al.
Estimating the costs attributable to a disease with application to ovarian cancer
J Clin Epidemiol
(1996) - et al.
Does prevention save costs?Considering deferral of the expensive last year of life
J Health Econ
(2005) - et al.
Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polypsThe National Polyp Study Workgroup
- et al.
Cost-effectiveness of screening for colorectal cancer in the general population
JAMA
(2000) About SEER
- et al.
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population
Med Care
(2002) - et al.
National estimates of medical costs incurred by nonelderly cancer patients
Cancer
(2004)
The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study
Health Econ
Cited by (84)
Cost of treating metastatic colorectal cancer: a systematic review
2022, Public HealthCitation Excerpt :Table 2, found in the Supplementary material, summarises the characteristics of each study. Fourteen studies were from the United States18–31 but there was also a broad international representation including Spain (n = 4),32–35 China (n = 2),36,37 France (n = 1),38 Korea (n = 1),39 Jordan (n = 1),40 Iran (n = 1),41 UK (n = 1),42 Switzerland (n = 1),43 Belgium (n = 1),44 Australia (n = 1),45 and Taiwan (n = 1).46 There were no studies from low-income countries.
Cost-effectiveness analysis of colorectal cancer screening in Shanghai, China: A modelling study
2022, Preventive Medicine ReportsPatient–Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care
2020, Value in HealthCitation Excerpt :Especially for patients with cancer, the impact of financial hardship appears to be more severe because cancer care and treatment are often costly.4 The estimated lifetime cost of cancer ranges from $150,000 to $200,000 (in 2018 USD),7-11 with cancer drugs contributing $100 000 per year on average and as much as $400,000 per course of treatment.4,11,12 Even for insured patients with cancer, prior data demonstrate that patients with employer-sponsored coverage still face up to $24,000 in out-of-pocket costs, which is equivalent to almost 60% of the average US household annual income.11,13
Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer
2018, European Journal of Surgical Oncology
The authors disclose the following: This study was sponsored by a grant from GE Healthcare, Waukesha, WI. D.W.L. is an employee of GE Healthcare; K.L., L.M.L., J.R.K., and J.M. received research funding from GE Healthcare; and C.C.E. is a consultant for Boston Health Economics.